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Purpose: To formulate and characterize indomethacin (IM) microspheres prepared with sugar cane wax 
microsperes.  
Methods: Microspheres were prepared by melt-emulsified dispersion and cooling-induced solidification 
method. The microspheres were characterized by scanning electron microscopy (SEM) and differntial 
scanning calorimetry (DSC) as well as for drug loading, and in vitro and in vivo release in albino sheeps. 
Results: SEM images showed that the microspheres were spherical in shape and more than 98.0 % of 
the isolated microspheres were in the size range 345 - 360 µm. The Cmax, Tmax, AUCO - 24 and T1/2 
values were 2123 ± 30 ng/ml, 3.1 h, 9734 ± 126 ng/ml h−1, and 2.68 ± 0.03 h−1 for the reference product, 
Microcid® SR, and 1989 ± 26 ng/ml, 3.0 h, 8013 ± 79 ng/ml h−1, and 2.79 ± 0.12 h−1, respectively, for the 
test formulation.  
Conclusion: Based on this study, it can be concluded  that the developed indomethacin-loaded wax  
microsheres and  Microcid® SR capsule are bioequivalent in terms of rate and extent of absorption. 
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INTRODUCTION 
 
Bioavailability and bioequivalence of drug 
products have emerged as critical issues in 
pharmacy and medicine in the last three 
decades. Also, in recent years, wax and fat-
based microspheres have found applications 
in drug delivery [1].The goal of any drug 
delivery system is to provide therapeutic 
amount of drug(s) to the proper site in the 
body in order to promptly achieve and 
maintain the desired drug concentrations 
during treatment. Poorly water-soluble drugs, 
which are lipophilic in nature, easily mix with 
waxes and show good absorption rate. 
However, reported methods are not suitable 
for all drugs and they depend on the nature of 
drug and its end use. Among the reported 
conventional methods, different strategies 
have been developed in recent years to 
design wax microspheres loaded with 
hydrophilic and lipophilic drugs using toxic 
solvents. The use of such solvents during 
formulation is of environmental concern and 
also detrimental to human safety.  
 
Sugarcane wax has good pharmaceutical 
and biological properties. Nearly 60 - 70 % of 
octacosanol present in sugarcane wax has 
been shown to reduce cholesterol and 
triglyceride levels. It contains long-chain 
carbohydrates with an OH radical or CHO 
radical, often known as octacosanal and 
octocosanol [2]. The lipid content, i.e., "cane 
wax", is extracted from cane molasses. The 
wax is hard, but oily to touch, and is devoid of 
taste or smell, making it very useful as an 
ingredient in food and as a pharmaceutical 
excipient, especially in cerates [3]. 
 
Indomethacin (IM) is a non-steroidal, anti-
inflammatory agent with antipyretic, analgesic 
properties and it is an indole derivative. It is 
widely used in the treatment of moderate to 
severe stages of rheumatoid arthritis and is 
given at least 2–3 times per day. Due to its 
narrow therapeutic index, the frequency of 
adverse effects is dose-related [5]. 
Considering the long regimen of osteoarthritis 
therapy, the administration of IM may induce 
adverse side effects on the gastrointestinal 
tract (GIT), as well as the central nervous, 
renal and cardiac systems [6]. The 
occurrence of these adverse effects can be 
reduced by the use of controlled release 
formulations [7]. Oral conventional dosage 
forms are administered 2–3 times a day to 
maintain adequate and effective therapeutic 
concentration in blood However; it fails to 
protect the patients against morning stiffness 
[8]. 
 
Thus, the development of a controlled 
release formulation of IM would afford several 
advantages over the other conventional 
dosage forms, including reduction in high 
initial peak plasma concentrations, protection 
against morning stiffness, prolonged duration 
of action, improved bioavailability, patient 
compliance and reduction in adverse effects 
[9] . The side effects could be lowered by 
controlling drug release and modifying 
absorption rate. The present study is 




Materials   
 
Indomethacins (IM), pure drug and 
mefanamic acid (MA), the internal standard, 
were kindly donated by Micro Labs 
(Bangalore, India). Sugarcane wax (melting 
point, 45 – 48 °C) was procured from Mandya 
Sugar Factory, Karnataka, India. Tween 80, 
and all other chemicals and solvents used 
were of analytical grade and purchased from 
Ranbaxy Fine Chemicals (New Delhi, India). 
A commercially available oral capsule 
formulation (Microcid® SR, 75 mg, Micro Labs 
Ltd, India) was used as a reference standard 
in this study.  
 
Preparation of microspheres  
 
Sugarcane wax (9 g) was melted in a china 
dish over a hot water bath and IM (3 g), 
previously passed through a 120 µ aperture 
sieve, was dispersed in it and stirred to obtain 
a homogeneous mixture. The mixture was 
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poured into 150 ml of phthalate buffer 
solution (pH 5.0), previously heated to a 
temperature higher (by > 5 0C) than the 
melting point of sugarcane wax. A surfactant, 
Tween 80 (0.2 % w/w), was added and 
stirred mechanically at 900 rpm with a stirrer 
(model RQ 127A, Remi Mumbai, India). The 
resulting spherical particles were stirred 
continuously above the melting point of wax 
at 900 rpm for 5 min. The temperature of the 
mixture was cooled rapidly to 10 0C by the 
addition of cold water. The solid spheres 
formed were collected by filtration and 
washed with water to remove surfactant 
residue. Air-drying was carried out at room 
temperature for 48 h to give discrete, solid, 
free flowing microspheres. A total of five 
formulations were prepared by varying the 




Wax microspheres were determined using a 
tap density tester and and Carr’s index (% I) 
was calculated using Eq 1. 
% I = (tapped density --  bulk density) / 
tapped density ………………….…………(1)      
 Angle of repose, Tan (θ), was assessed by a 
fixed funnel method to ascertain the 
flowability of the microspheres, and 
calculated as in Eq 2. 
 
Tan (θ) = h/r  ……………………………… (2)   
 
where h is the height of the pile and r the 
radius of the base of the pile.   
 
Scanning electron microscopy  
Scanning electron microscope (SEM) 
photomicrographs were recorded using Joel- 
LV-5600 SEM, USA. To determine sphericity, 
the tracings of wax microspheres 
(magnification, x459) were taken on a black 
paper using Lucida camera (Prism type, 
Rolex, India), and the sphericity factor (S) 
was calculated using Eq 3. 
 
S = p2 / (12.56A) ………………………..  (3)           
 
where, A is the area (cm2) and p the 
perimeter of the microsphere (cm)  
 
Differential scanning calorimetry (DSC) 
 
Dynamic DSC characterization was carried  
out on the microspheres using a DuPont 
thermal analyzer with a 2010 DSC module..  
 
Determination of drug loading 
 
The amount of drug incorporated in the 
microspheres was evaluated bu first 
powdering the microspheres (100 mg) in a 
mortar. The drug was extracted from the 
microspheres using methanol (100 ml), 
filtered and analyzed for drug content after 
suitable dilution with phosphate buffer (pH 
7.2), using a UV/visible spectrophotometer 
(Shimadzu – 1601, Japan) at a wavelength of 
319 nm. 
 
In vitro studies 
 
USP XX1 dissolution apparatus type II was 
employed to study drug release from the 
microspheres. An accurately weighed 
quantity of the microspheres (equivalent to 75 
mg of IM) was placed in 900 ml dissolution  
medium (hydrochloric acid buffer, pH 1.2), 
stirred at 100 rpm, for 2 h. in the dissolution 
medium was changed to (phosphate buffer, 
pH 7.2) and the dissolution process 
continued for another 6 h. The temperature 
was maintained at 37 ± 0.5 °C. The drug 
concentrations were determined by 
withdrawing the Aliquots (10 ml) of the 
dissolution medium were withdrawn at time 
intervals using guarded sample collectors, 
and analyzed spectrophometerically at 319 
nm. 
 
In vivo studies  
 
In vivo release studies were conducted in 
healthy adult albino sheep. Their age was in 
the range 6 - 8 years and body weight 30 to 
32 kg. A written approval (no. 004/2001) was 
obtained from the institutional ethical 
committee of JSS Medical College Hospital 
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and JSS College of Pharmacy, Mysore, India. 
The study was an open, randomized 
complete cross-over design in which a single 
75 mg dose of IM (Microcid® SR 75 mg 
capsule or test formulation F3) was 
administered to fasted, healthy adult males 
and females on two different occasions, 
separated by a washout period of 2 weeks 
between dosing. Blood samples (5 ml) were 
collected at 0 h (pre-dose) and at 0.5, 1, 1.5, 
2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 20 and 24 
h post-dose. The blood samples were 
centrifuged at 1500 rpm for 10 min and the 
separated plasma stored at –20  oC prior to 
analysis [18].  
 
Chromatographic studies  
 
IM concentrations in plasma were assayed 
using a fully validated high performance liquid 
chromatography (HPLC) [16[. The HPLC 
system used (model LC-6A, Shimadzu, 
Tokyo, Japan) was fitted with a µ -Bondapack 
C18 (4.6 x 250 mm) column of particle size (5 
µm, Supelco, Bellefonte, PA, USA). The flow 
rate was maintained at 1 µL/min; drug 
concentration was detected using a 
UV/visible detector (SPD- 6Av). The mobile 
phase consisted of 80 % methanol and 
0.02M sodium acetate buffer (60:40 v/v). The 
pH of the acetate buffer was 3.6. The column 
was heated to 40 oC and the wavelength was 
set at 320 nm.  
 
Pharmacokinetic and data analysis  
 
Pharmacokinetic parameters were 
calculated using Quick calk, computer 
PK calculation programme. The extent of 
absorption of Microcid® SR 75 mg 
capsule and test formulation (F3) in 
sheep was derived from the  area under 
the plasma concentration time curve 
from zero to 24 h (AUC 0–24) calculated 
by the trapezoidal rule method. Area 
under the plasma concentration time 
curve from zero to infinity (AUC 0-inf) was 
calculated as in Eq 4. 
 
AUC0 -∞ = AUC 0 -t + C24/K  ………… (4) 
 
where, C24 = drug concentration in 
plasma at 24 h, K the constant, t the 
time. Drug plasma concentration and 
pharmacokinetic parameters were 
analyzed by paired t- test and analysis of 
variance (ANOVA) at 95 % confidence 
limit. Difference between two related 
means was considered statistically 
significant when their p values were 






Mean size of the microsphere ranged from 
345 to 360 µm, as presented in Table 1. A 
wax:drug ratio of 1:3 was found to be 
optimum for the preparation of the 
microspheres (Table 1). A similar finding was 
previously reported by Gowda et al for 
wax/fat microspheres [10,12,14]. 
 
The micromeritic properties of the 
microspheres are given in Table 1. The 
angles of repose, tap density and car’s index 
were well within limits, indicating good flow of 
the microspheres as shown in Table 1.  
 


















F1 2.8 8.8 245 92.41 27 10 0.46 
F2 2.9 8.9 249 93.45 26 10 0.48 
F3 3.0 9.0 252 96.02 27 12 0.51 
F4 3.1 9.1 254 90.12 25 11 0.48 
F5 3.2 9.2 260 90.49 26 15 0.51 
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SEM photographs showed that the 
microspheres were spherical, non-
aggregated (Fig 1a), and had generally a 
smooth surface with some inward dents and 
shrinkage (Fig 1b), due probably to the 
collapse of the wall of the microspheres. The 
rate of solvent removal from the 
microspheres exerts an influence on the 




Fig 1: SEM photomicrograph of; (a) the exterior 
surface of indomethacin (IM)-loaded F3 




DSC studies on the pure drug, as well as on 
the blank and drug-loaded microspheres 
showed sharp endothermic peaks (Fig 2). IM 
exhibited a sharp endothermic peak at 161.3 
0C while. 
 
Fig 2: DSC thermogram of (a) pure indomethacin, 
(b) plain microspheres, and (c) indomethacin-
loaded  microspheres (F3) 
 
Drug-loading and encapsulation efficiency 
of the microspheres 
 
Drug loading in the formulations was in the 
range of 19.1 - 22.1 % while encapsulation 




The drug content of Microcid® SR capsule 
and formulation F3 were 99.66 and 99.51 %, 
respectively. Thus, the drug content was well 
within the stipulated limits (98% w/v to 107% 
w/v) of the United State Pharmacopoeia 
/National Formulary [16] for the two 
formulations. 
 
Drug release  
 
There was no significant release of drug at 
gastric pH from the test microspheres. At the 
end of 8 h, in vitro drug release from F3 (95.3 
%), was lower than from Microcid® SR (99.1 
%). Drug release was biphasic manner 
consisting of initial fast release followed by a 
slow release in intestinal pH from the wax 
microspheres [2,10,12,18]. 
 
Pharmacokinectics of indomethacin 
 
The mean plasma drug concentration as a 
function of time is shown in Fig 3 while the 
determined pharmacokinetic data for 
Microcid® SR and F3 formulations are given 
in Table 2. Mean plasma concentrations 
(Cmax) of IM for both preparations were within 
therapeutic  concentration range (300 – 3000 
ng/ml) in humans. [9]. Cmax fell below 
detection limit (50 ng/ml) after 24 h in all 
animals following administration of either 
product. On the basis of the data ontained, it 
can be predicted that the therapeutic activity 
of both formulations would be sustained for 
about 12 h following a single dose 
administration.  
 
The time taken to reach peak plasma 
concentration (Tmax) for both the reference 
product and the test formulation (F3) were 
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     Table 2: Pharmacokinetic parameters of Microcid® SR  
 
 
not statistically different (p < 0.05, as shown 
in Table 2. 
 
Fig 3: Mean plasma drug concentrations – 
time profiles of IM from Microcid® SR (□) and    




Waxy materials have the physical 
properties suitable for preparing gastro-
resistant, biocompatible and 
biodegradable microspheres to release 
entrapped drug in intestinal lumen [13-
15,18].  
 
Using an aqueous medium that was 
alkaline, indomethacin (IM) solubility 
decreased while that of the encapsulated 
drug increased.  
 
The decrease in vitro drug release from the 
microspheres might be due largely to the 
hydrophobicity and influence of the molecular 
weight of wax. In vitro drug release was 
considerably retarded from the wax 
microspheres when compared to Microcid® 
SR. The rate of drug release followed first 
order release kinetics and the numerical data 
fitted into Peppas model which means that, 
the mechanism of drug release from the wax 
microspheres was non-Fickian diffusion. On 
the basis of United States Food and Drug 
Administration (FDA) recommendation, the 
two products, Microcid®SR and formulation 
F3, can be considered bioequivalent. Thus, 
the two formulations can be considered 
similar in terms of release characteristics,. 
Absence of high peak plasma drug 
concentrations (> 5000 ng/ml) are often 
associated with indomethacin adverse effects 




The test and reference formulations were 
bioequivalent based on both the in vitro and  
in vivo data obtained, Thus, indomethacin 
microspheres encapsulated in sugar wax 
microspheres by melt method showed good 
potential for controlled drug delivery systems. 
 
Parameter Microcid ® SR F3 Pure IM p value 
Tmax  (h) 3.0 2.9 3.0 < 0.05 
Cmax(ng /ml) 2142 ± 39 2089 ± 16 2189 ± 26 < 0.05 
T1/2 (h
-1) 2.48 ± 0.13
 2.49 ± 0.11 2.65 ± 0.12  < 0.05 
AUC0-24 
(ng/ml h-1) 
8634 ± 106 8523 ± 89 8713 ± 69 < 0.05 
AUC0-∞ 
(ng/ml h-1) 
9974 ± 78 9315 ± 103.11  9897 ± 81 < 0.05 
Ka ( h
-1) 0.3921 ± 0.001
 0.3882 ± 0.003 0.389 ± 0.003 < 0.05 
Kel ( h
-1) 0.283±0.004
 0.282±0.002 0.286±0.002 < 0.05 
MRT* 4.68 ± 0.03 4.53 ± 0.02 4.61 ± 0.03 < 0.05 
T1/2 values for Microcid
® SR and formulation F3 were similar: 2.48 ± 0.13 and 2.49 ± 0.11 
h−1, respectively. So also were the rate of absorption (Ka), 0.392 ± 0.001 and 0.388 ± 
0.003 h-1, respectively; elimination rate constant (Kel), 0.284 ± 0.012 h
-1 and  0.282 ± 
0.001 h-1, respectively; and AUC0-∞, 997 ± 78 and 9315 ± 103 ng/ml.h
-1, respectively. 
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